Two Sigma Advisers
RANI icon

Two Sigma Advisers’s Rani Therapeutics RANI Stock Holding History

Two Sigma Advisers’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-110,163
Closed -$151K – 2543
2024
Q4 		$151K Buy
+110,163
New +$231K ﹤0.01% 2163

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Advisers's RANI Position: Q1 2025 in Review

Two Sigma Advisers sold out of Rani Therapeutics (RANI) in Q1 2025, closing a stake of 110,163 shares — an estimated $151K sold.

Two Sigma Advisers first reported a position in RANI in Q4 2024 and held it in 1 quarter. The position peaked at $151K in Q4 2024. 38 funds tracked by Wall St. Rank hold RANI as of Q1 2025.

  • Two Sigma Advisers reported no remaining Rani Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 110,163 Rani Therapeutics shares in Q1 2025, an estimated $151K.
  • Two Sigma Advisers first reported a position in Rani Therapeutics in Q4 2024 and held it in 1 quarter.
  • Two Sigma Advisers's Rani Therapeutics position peaked at $151K in Q4 2024.
  • 38 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2025.

Based on Two Sigma Advisers's 13F filing for Q1 2025, filed 15 May 2025.